CLRB vs RMD

ResMed Inc.

(RMD) offers the better valuation at 21. 8x trailing P/E (18. 8x forward), making it the more compelling value choice. Analysts rate ResMed Inc. (RMD) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ResMed Inc.

(RMD) delivered a total return of +11. 0%, compared to -99. 2% for Cellectar Biosciences, Inc. (CLRB). Over 10 years, the gap is even starker: RMD returned +293. 8% versus CLRB's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ResMed Inc.

(RMD) is the lower-risk stock at 0. 66β versus Cellectar Biosciences, Inc. 's 1. 76β — meaning CLRB is approximately 168% more volatile than RMD relative to the S&P 500. On balance sheet safety, Cellectar Biosciences, Inc. (CLRB) carries a lower debt/equity ratio of 4% versus 14% for ResMed Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Cellectar Biosciences, Inc.

grew EPS 80. 1% year-over-year, compared to 37. 4% for ResMed Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus 0. 0% for Cellectar Biosciences, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus 0. 0% for CLRB. At the gross margin level — before operating expenses — RMD leads at 59. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, RMD (1.

0% yield) pays a dividend. CLRB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, ResMed Inc.

(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 1. 0% yield, +293. 8% 10Y return). Cellectar Biosciences, Inc. (CLRB) carries a higher beta of 1. 76 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RMD: +293. 8%, CLRB: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

RMD pays a dividend while CLRB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.